
Yvonne Riley-Poku, PharmD
Advertisement
Articles by Yvonne Riley-Poku, PharmD


The agent is the first oral therapy for this indication.

Pharmacists can offer guidance on proper use of therapies and encourage adherence to regimens.

Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.

Cholangiocarcinoma is a rare bile duct cancer, with physicians diagnosing approximately 8000 cases each year.

The American Cancer Society estimates that oncologists will diagnose about 34,920 new cases of multiple myeloma in 2021 with about 12,410 deaths expected to occur.
Advertisement
Latest Updated Articles
- Oncology Overview: Infigratinib for Advanced Cholangiocarcinoma
Published: August 24th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Imlunestrant Tablets for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
2
IMWG Consensus Risk Criteria Predicts Survival in Daratumumab Quadruplet Therapy
3
Linvoseltamab Monotherapy Elicits Promising ORR, MRD-Negativity in NDMM
4
How Pharmacists Support CDK4/6 Inhibitor Management and Patient Care
5